Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma.

The option to treat patients presenting with HER-2 overexpressed invasive breast carcinoma with Herceptin requires quantitative determination of the HER-2 status. The aim of this study was to retrospectively evaluate the HER-2 mRNA expression levels using quantitative real-time RT-PCR (Q-RT-PCR) in tissue samples from 44 primary breast carcinomas and compare the results with immunohistochemistry (IHC). To determine the cut-off for altered mRNA expression, a normalized HER-2 expression value was determined for 20 normal breast tissue RNAs. Gene expression was categorized into three groups: normal expression (mRNAs <3); moderate overexpression (3 < or = mRNAs < 10) and strong overexpression (mRNAs < or =10). More than 38% (17/44) displayed strong overexpression, 25% (11/44) moderate and 36.3% (16/44) normal expression. Compared to IHC, only 7/44 cases were slightly discordant: strong mRNA overexpression/2+ protein staining (1 case), moderate overexpression/ 1+ (3 cases) and moderate overexpression/3+ (3 cases). These results show a high concordance rate (84%) between Q-RT-PCR and IHC (p < 10(-4)). We conclude that Q-RT-PCR is a useful complementary method for determination of the HER-2 status.

[1]  E. Perez,et al.  Future options with trastuzumab for primary systemic and adjuvant therapy. , 2004, Seminars in oncology.

[2]  Lajos Pusztai,et al.  Targeted Therapy in Breast Cancer , 2004, Molecular & Cellular Proteomics.

[3]  S. Franco,et al.  Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.

[4]  M. Dowsett,et al.  Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.

[5]  O. Dietze,et al.  Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast Carcinoma , 2002, Laboratory Investigation.

[6]  Takashi Suzuki,et al.  Chromogenic in situ hybridization analysis of HER‐2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin®) therapy , 2001, Pathology international.

[7]  Caroline Lohrisch,et al.  The Predictive Value of HER2 in Breast Cancer , 2001, Oncology.

[8]  H A Lehr,et al.  Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. , 2001, American journal of clinical pathology.

[9]  I. Andrulis,et al.  Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. , 2001, American journal of clinical pathology.

[10]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[11]  R. Simon,et al.  Comparative methodological analysis of erbB‐2/HER‐2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use , 2000, Histopathology.

[12]  D. Larsimont,et al.  Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. , 2000, The American journal of pathology.

[13]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Piccart,et al.  The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  U. Lehmann,et al.  Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. , 2000, The American journal of pathology.

[16]  I. Bièche,et al.  Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.

[17]  D. Treré,et al.  c‐erbB‐2 over‐expression in amplified and non‐amplified breast carcinoma samples , 1999, International journal of cancer.

[18]  F. Révillion,et al.  ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.

[19]  F. Révillion,et al.  Quantification of c-erbB-2 gene expression in breast cancer by competitive RT-PCR. , 1997, Clinical chemistry.

[20]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Richards,et al.  EGF-Related Peptides and Their Receptors in Mammary Gland Development , 1997, Journal of Mammary Gland Biology and Neoplasia.

[22]  E. Gelmann,et al.  erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. , 1994, British Journal of Cancer.

[23]  S. Steinberg,et al.  Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. , 1989, Cancer research.

[24]  P. Quirke,et al.  Pattern of expression of c-erbB-2 oncoprotein in human fetuses. , 1989, British Journal of Cancer.

[25]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[26]  G. Riou,et al.  Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. , 1988, Oncogene research.